Browse ID3

Summary
SymbolID3
Nameinhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Aliases HEIR-1; bHLHb25; ID-like protein inhibitor HLH 1R21; class B basic helix-loop-helix protein 25; helix-loop-h ......
Chromosomal Location1p36.13-p36.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00010 Helix-loop-helix DNA-binding domain
Function

Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Involved in myogenesis by inhibiting skeletal muscle and cardiac myocyte differentiation and promoting muscle precursor cells proliferation. Inhibits the binding of E2A-containing protein complexes to muscle creatine kinase E-box enhancer. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001822 kidney development
GO:0006260 DNA replication
GO:0006275 regulation of DNA replication
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007623 circadian rhythm
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030903 notochord development
GO:0042476 odontogenesis
GO:0042692 muscle cell differentiation
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0045445 myoblast differentiation
GO:0045661 regulation of myoblast differentiation
GO:0045662 negative regulation of myoblast differentiation
GO:0045667 regulation of osteoblast differentiation
GO:0045668 negative regulation of osteoblast differentiation
GO:0048511 rhythmic process
GO:0048568 embryonic organ development
GO:0051052 regulation of DNA metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051147 regulation of muscle cell differentiation
GO:0051148 negative regulation of muscle cell differentiation
GO:0070542 response to fatty acid
GO:0071229 cellular response to acid chemical
GO:0071396 cellular response to lipid
GO:0071398 cellular response to fatty acid
GO:0071407 cellular response to organic cyclic compound
GO:0072001 renal system development
GO:0072750 cellular response to leptomycin B
GO:1901344 response to leptomycin B
Molecular Function GO:0003714 transcription corepressor activity
GO:0008134 transcription factor binding
GO:0043177 organic acid binding
GO:1901707 leptomycin B binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04350 TGF-beta signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
Reactome -
Summary
SymbolID3
Nameinhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Aliases HEIR-1; bHLHb25; ID-like protein inhibitor HLH 1R21; class B basic helix-loop-helix protein 25; helix-loop-h ......
Chromosomal Location1p36.13-p36.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ID3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ID3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21191065Lung CarcinomaInhibit immunity (T cell function)We have shown that galectin-1 is highly expressed in lung cancer cell lines, together with the serum and surgical samples from lung cancer patients. Functionally, lung cancer-derived galectin-1 has been shown to alter the phenotypes of monocyte-derived DCs (MdDCs) and impair alloreactive T cell response, concomitant with the increase of CD4(+)CD25(+)FOXP3(+) regulatory T cells. The regulatory effect of galectin-1 is mediated, in part, through its ability to induce, in an Id3 (inhibitor of DNA binding 3)-dependent manner, the expression of IL-10 in monocytes and MdDCs. Of note, significant upregulation of IL-10 was seen in tumor-infiltrating CD11c(+) DCs in human lung cancer samples.
Summary
SymbolID3
Nameinhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Aliases HEIR-1; bHLHb25; ID-like protein inhibitor HLH 1R21; class B basic helix-loop-helix protein 25; helix-loop-h ......
Chromosomal Location1p36.13-p36.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ID3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolID3
Nameinhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Aliases HEIR-1; bHLHb25; ID-like protein inhibitor HLH 1R21; class B basic helix-loop-helix protein 25; helix-loop-h ......
Chromosomal Location1p36.13-p36.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ID3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.2140.0239
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.7220.442
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8650.668
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7580.0897
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6830.708
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8520.709
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2080.694
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2610.834
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1310.925
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.810.721
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4140.671
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1140.439
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ID3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolID3
Nameinhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Aliases HEIR-1; bHLHb25; ID-like protein inhibitor HLH 1R21; class B basic helix-loop-helix protein 25; helix-loop-h ......
Chromosomal Location1p36.13-p36.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ID3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolID3
Nameinhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Aliases HEIR-1; bHLHb25; ID-like protein inhibitor HLH 1R21; class B basic helix-loop-helix protein 25; helix-loop-h ......
Chromosomal Location1p36.13-p36.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ID3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ID3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolID3
Nameinhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Aliases HEIR-1; bHLHb25; ID-like protein inhibitor HLH 1R21; class B basic helix-loop-helix protein 25; helix-loop-h ......
Chromosomal Location1p36.13-p36.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ID3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolID3
Nameinhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Aliases HEIR-1; bHLHb25; ID-like protein inhibitor HLH 1R21; class B basic helix-loop-helix protein 25; helix-loop-h ......
Chromosomal Location1p36.13-p36.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ID3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolID3
Nameinhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Aliases HEIR-1; bHLHb25; ID-like protein inhibitor HLH 1R21; class B basic helix-loop-helix protein 25; helix-loop-h ......
Chromosomal Location1p36.13-p36.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ID3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolID3
Nameinhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Aliases HEIR-1; bHLHb25; ID-like protein inhibitor HLH 1R21; class B basic helix-loop-helix protein 25; helix-loop-h ......
Chromosomal Location1p36.13-p36.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ID3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.